



Post-Translational Nuclear Protein Modification and High Vitamin-D Receptor Levels in Genetic Hypercalciuric Stone-Forming Rats

Journal of Health Disparities Research and Practice

Volume 9
Issue 5 Special Issue - NIDDK STEP UP

Article 64

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2016

Post-Translational Nuclear Protein Modification and High Vitamin-D Receptor Levels in Genetic Hypercalciuric Stone-Forming Rats

Armaan Goyal
Murray Favus, MD , *University of Chicago*

Follow this and additional works at: <https://digitalscholarship.unlv.edu/jhdrp>



Part of the Bilingual, Multilingual, and Multicultural Education Commons, Community College Leadership Commons, Higher Education Commons, Immune System Diseases Commons, Public Health Commons, Translational Medical Research Commons, and the Virus Diseases Commons

Recommended Citation

Goyal, Armaan and Favus, MD, Murray (2016) "Post-Translational Nuclear Protein Modification and High Vitamin-D Receptor Levels in Genetic Hypercalciuric Stone-Forming Rats," *Journal of Health Disparities Research and Practice*: Vol. 9: Iss. 5, Article 64.

Available at: <https://digitalscholarship.unlv.edu/jhdrp/vol9/iss5/64>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Journal of Health Disparities Research and Practice by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

Post-Translational Nuclear Protein Modification and High Vitamin-D Receptor Levels in Genetic Hypercalciuric Stone-Forming Rats

Abstract

Studies conducted on Genetic Hypercalciuric-Stone Forming (GHS) rats have shown that their excess calcium urine excretion might be caused by significantly high vitamin D receptor (VDR) levels found in key calcium-transporting tissues, since high VDR raises physiological response to 1,25(OH)₂D₃, the hormonally active metabolite of vitamin D that regulates calcium levels in the body. We suggest that the high VDR levels in GHS tissue are a result of altered post-translational modification by ubiquitin and Small Ubiquitin-like Modifier (SUMO), which regulate the degradation of nuclear proteins substrates such as VDR.

Our inquiry begins by overexpressing ubiquitin, SUMO-1, SUMO-2, and SUMO-3 in rat tissue to perform targeted gene expression of VDR. Western blot will be used to analyze resulting changes in the VDR signaling pathway and the degree to which the GHS rat phenotype is emulated with the added ubiquitin or SUMO. Our proceeding step will be to measure changes in VDR levels after performing an siRNA-facilitated knockdown of the E1, E2, and E3 enzymes that facilitate ubiquitination of nuclear proteins. Our final experiment will consist of isolating proteins from GHS bone marrow, intestinal, and renal cells and recording ubiquitin levels to compare with control tissue.

If there is a consistent trend in the ubiquitin levels of GHS cells compared to control cells, and the western blot and enzyme knockdown procedures reveal that altered ubiquitin/SUMO presence affects VDR levels, then there will be evidence to show that the general hypercalciuric phenotype could be an eventual result of insufficient VDR degradation due to abnormal post-translational protein modification.

Keywords

SUMO: Ubiquitin; Hypercalciuria; Protein Degradation



Journal of Health Disparities Research and Practice

Volume 9, Special Edition 1, Summer 2016, pp. 95

© 2011 Center for Health Disparities Research

School of Community Health Sciences

University of Nevada, Las Vegas

Post-Translational Nuclear Protein Modification and High Vitamin-D Receptor Levels in Genetic Hypercalciuric Stone-Forming Rats

Armaan Goyal

Murray Favus, MD, University of Chicago

Coordinating Center: Stanford University

ABSTRACT

Studies conducted on Genetic Hypercalciuric-Stone Forming (GHS) rats have shown that their excess calcium urine excretion might be caused by significantly high vitamin D receptor (VDR) levels found in key calcium-transporting tissues, since high VDR raises physiological response to $1,25(\text{OH})_2\text{D}_3$, the hormonally active metabolite of vitamin D that regulates calcium levels in the body. We suggest that the high VDR levels in GHS tissue are a result of altered post-translational modification by ubiquitin and Small Ubiquitin-like Modifier (SUMO), which regulate the degradation of nuclear proteins substrates such as VDR.

Our inquiry begins by overexpressing ubiquitin, SUMO-1, SUMO-2, and SUMO-3 in rat tissue to perform targeted gene expression of VDR. Western blot will be used to analyze resulting changes in the VDR signaling pathway and the degree to which the GHS rat phenotype is emulated with the added ubiquitin or SUMO. Our proceeding step will be to measure changes in VDR levels after performing an siRNA-facilitated knockdown of the E1, E2, and E3 enzymes that facilitate ubiquitination of nuclear proteins. Our final experiment will consist of isolating proteins from GHS bone marrow, intestinal, and renal cells and recording ubiquitin levels to compare with control tissue.

If there is a consistent trend in the ubiquitin levels of GHS cells compared to control cells, and the western blot and enzyme knockdown procedures reveal that altered ubiquitin/SUMO presence affects VDR levels, then there will be evidence to show that the general hypercalciuric phenotype could be an eventual result of insufficient VDR degradation due to abnormal post-translational protein modification.

Key Words: SUMO, Ubiquitin, Hypercalciuria, Protein Degradation

ACKNOWLEDGEMENTS

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, Grant number: R25DK078382.